Lorazepam intranasal - Intranasal Therapeutics

Drug Profile

Lorazepam intranasal - Intranasal Therapeutics

Latest Information Update: 22 May 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ikano Therapeutics
  • Class Antiemetics; Anxiolytics; Benzodiazepinones; Hypnosedatives; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anxiety disorders; Seizures; Sleep disorders

Most Recent Events

  • 22 May 2009 Discontinued - Phase-I for Anxiety disorders in USA (Intranasal)
  • 22 May 2009 Discontinued - Phase-I for Seizures in USA (Intranasal)
  • 08 Mar 2007 Intranasal lorazepam is still in phase I trials for anxiety disorders and seizures in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top